1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,340 | 2,480 | 19:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2025 ANNUAL RESULTS ... | 1 | HKEx | ||
| Mo | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* VOLUNTARY ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING ... | 1 | HKEx | ||
| 13.03. | Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates | 361 | GlobeNewswire (Europe) | SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to... ► Artikel lesen | |
| 13.03. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT | 1 | HKEx | ||
| 13.03. | JUNSHI BIO (01877): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT | 2 | HKEx | ||
| 13.03. | JUNSHI BIO (01877): ADJUSTMENT OF THE STRATEGIC COMMITTEE TO THE STRATEGIC AND ESG COMMITTEE; AMENDMENTS TO AND FORMULATION OF CERTAIN INTERNAL MANAGEMENT ... | 3 | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 13.03. | JUNSHI BIO (01877): TERMS OF REFERENCE OF THE STRATEGIC AND ESG COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 13.03. | JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 13.03. | JUNSHI BIO (01877): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | - | HKEx | ||
| 12.03. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RETURN OF IDLE PROCEEDS USED FOR TEMPORARY ... | - | HKEx | ||
| 10.03. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING ... | 1 | HKEx | ||
| 10.03. | Junshi receives China's NMPA acceptance for toripalimab injection | 2 | Pharmaceutical Technology | ||
| 09.03. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE NEW DRUG APPLICATIONS FOR TORIPALIMAB INJECTION (SUBCUTANEOUS INJECTION) | 1 | HKEx | ||
| 09.03. | Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications | 270 | GlobeNewswire (Europe) | SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to... ► Artikel lesen | |
| 02.03. | JUNSHI BIO (01877): DATE OF BOARD MEETING | 2 | HKEx | ||
| 27.02. | JUNSHI BIO (01877): INSIDE INFORMATION - 2025 PRELIMINARY RESULTS | 1 | HKEx | ||
| 25.02. | Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor) | 634 | GlobeNewswire (Europe) | SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 25.02. | Antengene Corporation Limited: Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb) | 671 | PR Newswire | SHANGHAI and HONG KONG, Feb. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global... ► Artikel lesen | |
| 10.02. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING ... | 1 | HKEx | ||
| 30.01. | JUNSHI BIO (01877): INSIDE INFORMATION - 2025 RESULTS FORECAST | 1 | HKEx |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ILLUMINA | 107,32 | -0,24 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| BRAIN BIOTECH | 2,300 | -1,71 % | BRAIN Biotech AG - Ruhe im Kursrückgang bewahren | ||
| OCUGEN | 1,759 | +1,24 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 27,835 | -0,50 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| TEMPUS AI | 40,800 | 0,00 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| EDITAS MEDICINE | 2,053 | +1,68 % | Is Editas Medicine Going to $0? | ||
| SAREPTA THERAPEUTICS | 14,710 | +1,62 % | Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,130 | -1,34 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| EXACT SCIENCES | 90,94 | +0,22 % | Abbott to close $21B Exact Sciences deal on March 23 | ||
| BASILEA | 56,90 | -0,70 % | BANCO BILBAO VIZCAYA ARGENTARIA, S.A.: The Company reports the 2025 "Prudential Relevance Report" (Pilar III Basilea) | ||
| IMMUNITYBIO | 7,440 | +0,30 % | Jim Cramer on ImmunityBio: "That Stock Is Part of the Magical Thinking Era" | ||
| XOMA ROYALTY | 24,400 | +0,83 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,008 | +2,01 % | IBA SA: Telix selects IBA Cyclone KIUBE to support manufacturing expansion in the U.S. | Louvain-la-Neuve, Belgium- March 20, 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 11,510 | -2,08 % | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen | |
| REPLIGEN | 97,00 | -0,47 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year... ► Artikel lesen |
Das Unternehmen SHANGHAI JUNSHI BIOSCIENCES CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,040 (-1,65 %) liegt der Kurs bei 2,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.